Developer docs
API playgroundTry for free, no card

Search company profiles

BostonGene

Full company profile

uuid00007fq

Namestring
BostonGene
Legal namestring
BostonGene Corporation
Websiteurl
bostongene.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies

Short descriptiontext

BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology analytics, multiomic molecular profiling, AI-driven biomarker discovery, clinical genomic sequencing, immune profiling services
Industry6 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers513210
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Precision Oncology Analytics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Biopharma Partnerships and Platform Services
TypeSubscription Recurring
Description

BostonGene generates revenue through strategic partnerships with biopharmaceutical organizations, providing AI-powered analytics platforms for drug development, patient selection, and clinical trial optimization. Engagements typically begin as focused pilots and expand into broader platform integration.

prnewswire.com
2Clinical Laboratory Testing Services
TypeProfessional Services
Description

BostonGene operates through its CLIA-certified, CAP-accredited laboratory providing molecular profiling services including whole exome sequencing, transcriptome sequencing, liquid biopsy, and immunoprofiling for healthcare providers and biopharma partners.

bostongene.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Enterprise biopharma partnerships with AI-powered analytics platform access
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based pricing for biopharma platform partnerships; engagements begin as focused pilots and expand into broader platform integration

bostongene.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Kassandra™
Description

AI-based tool that reconstructs tumor microenvironment from gene expression data

bostongene.com
+2 more records
Core offering1 text field

BostonGene provides a cloud-based AI-driven multimodal analytics platform that integrates whole exome sequencing, whole transcriptome sequencing, liquid biopsy, immune profiling, spatial proteomics, and digital pathology to analyze tumors, microenvironments, and host immunity. The company sells its BostonGene Tumor Portrait® test and related clinical assays to healthcare providers and oncologists, and offers AI-powered target identification, biomarker discovery, clinical trial support, and drug repurposing modules to biopharmaceutical partners via a subscription/enterprise model.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Identified actionable RNA findings in all enrolled patients in FEASY study
+2 more records
Product overview1 text field

BostonGene offers a cloud-based AI platform that integrates multiple molecular and immune profiling techniques to comprehensively analyze tumors, microenvironments, and host immunity for precision oncology. The platform combines whole exome sequencing, whole transcriptome sequencing, liquid biopsy (ctDNA/cfRNA), single-cell RNA sequencing, flow cytometry, spatial proteomics, and digital pathology into a unified system. For biopharma clients, the platform provides target identification, biomarker discovery, clinical trial support, drug repurposing, and unmet need identification modules. For healthcare providers, BostonGene offers the BostonGene Tumor Portrait test, Immune System Profiling, IHC testing, and Unknown Primary testing. The company operates its own CLIA-certified, CAP-accredited laboratory and partners with leading biopharmaceutical organizations and academic institutions.

Product and service14 records
1BostonGene Tumor Portrait® test
CategoryClinical Molecular Profiling
Description

Integrated solution providing a holistic 360° overview for each cancer patient, identifying key biomarkers for response to various therapies in patients with advanced solid tumors. Uses DNA whole exome and RNA transcriptome sequencing for comprehensive molecular profiling.

2Immune System Profiling
CategoryClinical Diagnostic Test
Description

Blood-based immune profiling providing a snapshot of the patient's immune health by identification of hundreds of different cell types from a single tube of blood, using flow cytometry and AI-based models.

3Immunohistochemistry (IHC) test
CategoryClinical Diagnostic Test
Description

AI-based testing for clinically actionable biomarkers such as PD-L1 and MMR with automated workflow applicable to various markers including nuclear, cytoplasm/membrane, and complex membrane markers.

4Unknown Primary test
CategoryClinical Diagnostic Test
Description

Identifies the tumor's origin using DNA and RNA sequencing to help guide treatment decisions for patients with cancers of unknown primary.

5Whole Transcriptome Sequencing (WTS / RNA-seq)
CategoryLaboratory Service
Description

Sequencing of nearly 20,000 genes enabling precise identification of gene fusions, expression levels, and gene expression signatures in a CLIA/CAP environment, with tumor microenvironment analysis, TCR/BCR repertoire, and HLA haplotyping.

6Whole Exome Sequencing (WES)
CategoryLaboratory Service
Description

Sequencing of nearly 20,000 genes providing uniform coverage across 99.7% of coding regions, enabling unbiased detection of genetic variants (SNVs, indels, CNAs, LOH, TMB, MSI) in a CLIA/CAP environment.

7Liquid Biopsy (ctDNA and cfRNA sequencing)
CategoryLaboratory Service
Description

Minimally invasive blood-based tumor profiling enabling identification of biomarkers and monitoring of treatment response at both DNA and RNA levels via ctDNA and cfRNA assays.

8Single-cell RNA sequencing
CategoryLaboratory Service
Description

High-resolution analysis of individual transcriptomes from thousands of cells within a single sample, revealing cell-specific transcriptional changes and identifying rare, functionally significant cell populations.

9Flow Cytometry
CategoryLaboratory Service
Description

State-of-the-art flow cytometry including analytical flow cytometry and cell sorting to assess immune system status from standard blood samples. Supports basic immunoprofiling (10 panels, >800 cell populations) and advanced immunoprofiling.

10Spatial Proteomics
CategoryLaboratory Service
Description

End-to-end multiplex immunofluorescence (MxIF) pipeline offering comprehensive overview of tissue architecture and cell-cell interactions by detecting up to 60 protein markers from a single slide with single-cell resolution.

11Digital Pathology
CategoryLaboratory Service
Description

AI-based digital pathology platform that identifies distinct characteristics of tumor and microenvironment, reducing need for manual analysis. Supports H&E analysis, IHC detection, and multiplex immunofluorescence from whole-slide images.

12Biomarker Discovery Platform
CategoryBiopharma Analytics
Description

AI-powered platform for biomarker discovery and validation, integrating multiomic data including genomics, transcriptomics, and immune profiling to improve patient selection, optimize trial design, and accelerate oncology drug development.

13Target Analysis Solution
CategoryBiopharma Analytics
Description

Leverages proprietary genomic and transcriptomic databases to pinpoint the most promising cancer types for drug candidates and identify novel therapeutic targets.

14Drug Repurposing Solutions
CategoryBiopharma Analytics
Description

AI-driven end-to-end drug repurposing platform discovering beneficial drug-disease matches to maximize the potential of existing drug portfolios.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Kyoto University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-07-22
Description

Strategic research partnership supporting multicenter Phase II clinical trial evaluating combined immune checkpoint inhibitors (ICI) and photodynamic therapy (PDT) for advanced gastrointestinal cancers. BostonGene applies its multimodal AI analytics platform to identify molecular signatures and immune-response patterns associated with therapeutic response.

bostongene.com
2Hokkaido University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-11
Description

Expanded multi-year strategic research collaboration to advance precision oncology in Japan. BostonGene conducts next-generation sequencing and integrated analysis of DNA, RNA, and immune profiles from tumor samples across more than 20 cancer types to identify patient-specific disease drivers and guide therapeutic decision-making.

finance.yahoo.com
3ImmunoGenesis
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Strategic partnership to accelerate clinical development of IMGS-001, a cytotoxic immune checkpoint inhibitor targeting both PD-L1 and PD-L2. BostonGene applies its AI-driven multiomic and spatial biology platform to perform molecular characterization and identify patients most likely to respond to treatment.

businesswire.com
4Unilever
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Strategic collaboration to apply advanced AI and multiomics approaches to scientific exploration and long-term innovation in consumer products. The partnership extends BostonGene's AI foundation model beyond oncology into consumer-focused science.

businesswire.com
5Daiichi Sankyo
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Strategic collaboration to integrate AI-driven translational intelligence into Daiichi Sankyo's antibody drug conjugate (ADC) development program. BostonGene generates digital twin representations from hundreds of thousands of multiomic and histopathologic patient profiles to enable precise patient selection and optimize clinical trial design.

morningstar.com
6AstraZeneca
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

Strategic collaboration to advance oncology drug development using BostonGene's multimodal AI platform. AstraZeneca applies BostonGene's omnimodal analytics to deliver predictive insights on patient-level safety and efficacy outcomes in early clinical trials, accelerating development timelines and reducing risk across its oncology portfolio.

biospace.com
7Takeda
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-01
Description

Partnership to leverage BostonGene's AI-powered multiomics platform in select early-stage clinical trials. BostonGene performs sophisticated multiomic analytics including flow cytometry, RNA-seq, and proteomics data to enhance trial design, improve indication selection, and identify biomarker signatures for response and toxicity.

bostongene.com
8MD Anderson Cancer Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research in FEASY study published in Cancer Discovery demonstrating that RNA-based multiomic analysis identified new therapeutic targets for antibody-drug conjugates in patients with advanced solid tumors who previously had no actionable results from DNA testing alone.

biospace.com
9Memorial Sloan Kettering Cancer Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research demonstrating integrated molecular profiling for refining risk assessment, predicting CAR-T therapy resistance, and identifying biomarkers for patient selection in blood cancers. Partnership on multi-omic profiling to identify genomic subtypes associated with differential outcomes after CAR-T therapy.

businesswire.com
10Weill Cornell Medicine
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research on AI-driven multiomics platforms for blood cancer treatment optimization including CAR-T therapy outcomes and lymphoma research.

businesswire.com
11Friends of Cancer Research
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on landmark blinded, multi-vendor HER2 benchmarking study published in Modern Pathology. BostonGene's AI foundation model received independent validation achieving high agreement rates across 10 AI models for assessing HER2 expression in breast cancer.

businesswire.com
12UT MD Anderson Cancer Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research on integrated transcriptomic and immune profiling for chronic lymphocytic leukemia treatment, pancreatic cancer KRAS/MTAP analysis, and multiple myeloma risk stratification research.

bostongene.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Tempus AI
TypeDirect peer
Description

Tempus AI is the most direct competitor, offering a multimodal AI platform that integrates genomic, transcriptomic, imaging, and clinical data for biopharma R&D and clinical oncology decision support — overlapping with BostonGene across both biopharma partnerships and clinical diagnostics offerings.

2Foundation Medicine
TypeDirect peer
Description

Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) used widely for therapy selection and biopharma trial enrollment — directly overlapping with BostonGene's Tumor Portrait and biopharma patient stratification offerings.

3Caris Life Sciences
TypeDirect peer
Description

Caris offers MI Profile and Caris Assure for multiomic tumor profiling plus biopharma services including Caris Discovery — directly comparable to BostonGene's combined lab services and biopharma platform strategy in precision oncology.

4Personalis
TypeDirect peer
Description

Personalis provides ImmunoID Next and NeXT Personal liquid biopsy tests and biopharma services for tumor molecular profiling — overlapping with BostonGene's WES/WTS, liquid biopsy, and biopharma analytics offerings.

5PathAI
TypeDirect peer
Description

PathAI builds AI-powered pathology and biomarker platforms deployed with biopharma for clinical trial analytics and companion diagnostics — directly comparable to BostonGene's digital pathology and biopharma AI platform modules.

6Owkin
TypeDirect peer
Description

Owkin operates an AI platform for patient stratification, biomarker discovery, and trial optimization serving biopharma — directly overlapping with BostonGene's biopharma target identification, biomarker discovery, and clinical trial support modules.

7Guardant Health
TypeBroad incumbent
Description

Guardant Health is a liquid biopsy leader (Guardant360, Reveal) with a broader commercial footprint and FDA-approved diagnostics — overlapping with BostonGene's liquid biopsy (cfDNA/cfRNA) services but with established payer coverage and a public market scale BostonGene does not yet have.

8Natera
TypeEmerging player
Description

Natera's Signatera MRD test and oncology offerings compete in molecular monitoring and treatment response — partial overlap with BostonGene's liquid biopsy and treatment-response monitoring services, primarily in the clinical rather than biopharma channel.

9Paige AI
TypeDirect peer
Description

Paige builds AI-based digital pathology models including Paige Prostate (FDA-authorized) for cancer diagnosis and biopharma applications — directly comparable to BostonGene's AI-based digital pathology, IHC detection, and HER2 benchmarking work.

10Recursion Pharmaceuticals
TypeEmerging player
Description

Recursion applies AI foundation models across multiomic and imaging data for drug discovery, with biopharma partnerships — adjacent to BostonGene's biopharma AI platform and foundation-model approach, though Recursion focuses more on therapeutic discovery rather than trial analytics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BostonGene

Precision Oncology Analyticsbostongene.com

BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.

What BostonGene does

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies

BostonGene firmographics

Firmographics
Name
BostonGene
Legal name
BostonGene Corporation
Website
https://bostongene.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Short description
BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.
Ownership category
akta.pro rank

BostonGene industry classification

Industry
Product category
Precision Oncology Analytics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Precision oncology analytics
  • Multiomic molecular profiling
  • AI-driven biomarker discovery
  • Clinical genomic sequencing
  • Immune profiling services

Where BostonGene is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BostonGene business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Biopharma Partnerships and Platform Services: BostonGene generates revenue through strategic partnerships with biopharmaceutical organizations, providing AI-powered analytics platforms for drug development, patient selection, and clinical trial optimization. Engagements typically begin as focused pilots and expand into broader platform integration.
  2. Clinical Laboratory Testing Services: BostonGene operates through its CLIA-certified, CAP-accredited laboratory providing molecular profiling services including whole exome sequencing, transcriptome sequencing, liquid biopsy, and immunoprofiling for healthcare providers and biopharma partners.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise biopharma partnerships with AI-powered analytics platform access

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

BostonGene product offering

Product offering

Core offering

BostonGene provides a cloud-based AI-driven multimodal analytics platform that integrates whole exome sequencing, whole transcriptome sequencing, liquid biopsy, immune profiling, spatial proteomics, and digital pathology to analyze tumors, microenvironments, and host immunity. The company sells its BostonGene Tumor Portrait® test and related clinical assays to healthcare providers and oncologists, and offers AI-powered target identification, biomarker discovery, clinical trial support, and drug repurposing modules to biopharmaceutical partners via a subscription/enterprise model.

Product overview

BostonGene offers a cloud-based AI platform that integrates multiple molecular and immune profiling techniques to comprehensively analyze tumors, microenvironments, and host immunity for precision oncology. The platform combines whole exome sequencing, whole transcriptome sequencing, liquid biopsy (ctDNA/cfRNA), single-cell RNA sequencing, flow cytometry, spatial proteomics, and digital pathology into a unified system. For biopharma clients, the platform provides target identification, biomarker discovery, clinical trial support, drug repurposing, and unmet need identification modules. For healthcare providers, BostonGene offers the BostonGene Tumor Portrait test, Immune System Profiling, IHC testing, and Unknown Primary testing. The company operates its own CLIA-certified, CAP-accredited laboratory and partners with leading biopharmaceutical organizations and academic institutions.

Differentiator

Problem solved

Functional benefit

Brands

  • Kassandra™: AI-based tool that reconstructs tumor microenvironment from gene expression data
  • BostonGene Tumor Portrait® test
  • PAM50(BG)

Products and services

  • BostonGene Tumor Portrait® test Integrated solution providing a holistic 360° overview for each cancer patient, identifying key biomarkers for response to various therapies in patients with advanced solid tumors. Uses DNA whole exome and RNA transcriptome sequencing for comprehensive molecular profiling.
  • Immune System Profiling Blood-based immune profiling providing a snapshot of the patient's immune health by identification of hundreds of different cell types from a single tube of blood, using flow cytometry and AI-based models.
  • Immunohistochemistry (IHC) test AI-based testing for clinically actionable biomarkers such as PD-L1 and MMR with automated workflow applicable to various markers including nuclear, cytoplasm/membrane, and complex membrane markers.
  • Unknown Primary test Identifies the tumor's origin using DNA and RNA sequencing to help guide treatment decisions for patients with cancers of unknown primary.
  • Whole Transcriptome Sequencing (WTS / RNA-seq) Sequencing of nearly 20,000 genes enabling precise identification of gene fusions, expression levels, and gene expression signatures in a CLIA/CAP environment, with tumor microenvironment analysis, TCR/BCR repertoire, and HLA haplotyping.
  • Whole Exome Sequencing (WES) Sequencing of nearly 20,000 genes providing uniform coverage across 99.7% of coding regions, enabling unbiased detection of genetic variants (SNVs, indels, CNAs, LOH, TMB, MSI) in a CLIA/CAP environment.
  • Liquid Biopsy (ctDNA and cfRNA sequencing) Minimally invasive blood-based tumor profiling enabling identification of biomarkers and monitoring of treatment response at both DNA and RNA levels via ctDNA and cfRNA assays.
  • Single-cell RNA sequencing High-resolution analysis of individual transcriptomes from thousands of cells within a single sample, revealing cell-specific transcriptional changes and identifying rare, functionally significant cell populations.
  • Flow Cytometry State-of-the-art flow cytometry including analytical flow cytometry and cell sorting to assess immune system status from standard blood samples. Supports basic immunoprofiling (10 panels, >800 cell populations) and advanced immunoprofiling.
  • Spatial Proteomics End-to-end multiplex immunofluorescence (MxIF) pipeline offering comprehensive overview of tissue architecture and cell-cell interactions by detecting up to 60 protein markers from a single slide with single-cell resolution.
  • Digital Pathology AI-based digital pathology platform that identifies distinct characteristics of tumor and microenvironment, reducing need for manual analysis. Supports H&E analysis, IHC detection, and multiplex immunofluorescence from whole-slide images.
  • Biomarker Discovery Platform AI-powered platform for biomarker discovery and validation, integrating multiomic data including genomics, transcriptomics, and immune profiling to improve patient selection, optimize trial design, and accelerate oncology drug development.
  • Target Analysis Solution Leverages proprietary genomic and transcriptomic databases to pinpoint the most promising cancer types for drug candidates and identify novel therapeutic targets.
  • Drug Repurposing Solutions AI-driven end-to-end drug repurposing platform discovering beneficial drug-disease matches to maximize the potential of existing drug portfolios.

Quantifiable outcome

  • Identified actionable RNA findings in all enrolled patients in FEASY study
  • +2 more outcomes

Companies that use BostonGene

Customer profile

Named customers12 records

Segments3 records

Ideal customer profiles2 records

BostonGene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability7 records

Feature11 records

BostonGene partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, minor and flagship.

  • Kyoto UniversitycoreStrategic or Co-development Partner · 22 July 2026Strategic research partnership supporting multicenter Phase II clinical trial evaluating combined immune checkpoint inhibitors (ICI) and photodynamic therapy (PDT) for advanced gastrointestinal cancers. BostonGene applies its multimodal AI analytics platform to identify molecular signatures and immune-response patterns associated with therapeutic response.
  • Hokkaido UniversitycoreStrategic or Co-development Partner · 11 May 2026Expanded multi-year strategic research collaboration to advance precision oncology in Japan. BostonGene conducts next-generation sequencing and integrated analysis of DNA, RNA, and immune profiles from tumor samples across more than 20 cancer types to identify patient-specific disease drivers and guide therapeutic decision-making.
  • ImmunoGenesiscoreStrategic or Co-development Partner · 14 April 2026Strategic partnership to accelerate clinical development of IMGS-001, a cytotoxic immune checkpoint inhibitor targeting both PD-L1 and PD-L2. BostonGene applies its AI-driven multiomic and spatial biology platform to perform molecular characterization and identify patients most likely to respond to treatment.
  • UnileverminorStrategic or Co-development Partner · 3 March 2026Strategic collaboration to apply advanced AI and multiomics approaches to scientific exploration and long-term innovation in consumer products. The partnership extends BostonGene's AI foundation model beyond oncology into consumer-focused science.
  • Daiichi SankyoflagshipStrategic or Co-development Partner · 17 February 2026Strategic collaboration to integrate AI-driven translational intelligence into Daiichi Sankyo's antibody drug conjugate (ADC) development program. BostonGene generates digital twin representations from hundreds of thousands of multiomic and histopathologic patient profiles to enable precise patient selection and optimize clinical trial design.
  • AstraZenecaflagshipStrategic or Co-development Partner · 6 January 2026Strategic collaboration to advance oncology drug development using BostonGene's multimodal AI platform. AstraZeneca applies BostonGene's omnimodal analytics to deliver predictive insights on patient-level safety and efficacy outcomes in early clinical trials, accelerating development timelines and reducing risk across its oncology portfolio.
  • TakedacoreStrategic or Co-development Partner · 1 August 2024Partnership to leverage BostonGene's AI-powered multiomics platform in select early-stage clinical trials. BostonGene performs sophisticated multiomic analytics including flow cytometry, RNA-seq, and proteomics data to enhance trial design, improve indication selection, and identify biomarker signatures for response and toxicity.
  • MD Anderson Cancer CentercoreStrategic or Co-development PartnerCollaborative research in FEASY study published in Cancer Discovery demonstrating that RNA-based multiomic analysis identified new therapeutic targets for antibody-drug conjugates in patients with advanced solid tumors who previously had no actionable results from DNA testing alone.
  • Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerCollaborative research demonstrating integrated molecular profiling for refining risk assessment, predicting CAR-T therapy resistance, and identifying biomarkers for patient selection in blood cancers. Partnership on multi-omic profiling to identify genomic subtypes associated with differential outcomes after CAR-T therapy.
  • Weill Cornell MedicinecoreStrategic or Co-development PartnerCollaborative research on AI-driven multiomics platforms for blood cancer treatment optimization including CAR-T therapy outcomes and lymphoma research.
  • Friends of Cancer ResearchcoreStrategic or Co-development PartnerCollaboration on landmark blinded, multi-vendor HER2 benchmarking study published in Modern Pathology. BostonGene's AI foundation model received independent validation achieving high agreement rates across 10 AI models for assessing HER2 expression in breast cancer.
  • UT MD Anderson Cancer CentercoreStrategic or Co-development PartnerCollaborative research on integrated transcriptomic and immune profiling for chronic lymphocytic leukemia treatment, pancreatic cancer KRAS/MTAP analysis, and multiple myeloma risk stratification research.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

BostonGene competitors and assessment

Company assessment

Direct peers

  • Tempus AI: Tempus AI is the most direct competitor, offering a multimodal AI platform that integrates genomic, transcriptomic, imaging, and clinical data for biopharma R&D and clinical oncology decision support — overlapping with BostonGene across both biopharma partnerships and clinical diagnostics offerings.
  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) used widely for therapy selection and biopharma trial enrollment — directly overlapping with BostonGene's Tumor Portrait and biopharma patient stratification offerings.
  • Caris Life Sciences: Caris offers MI Profile and Caris Assure for multiomic tumor profiling plus biopharma services including Caris Discovery — directly comparable to BostonGene's combined lab services and biopharma platform strategy in precision oncology.
  • Personalis: Personalis provides ImmunoID Next and NeXT Personal liquid biopsy tests and biopharma services for tumor molecular profiling — overlapping with BostonGene's WES/WTS, liquid biopsy, and biopharma analytics offerings.
  • PathAI: PathAI builds AI-powered pathology and biomarker platforms deployed with biopharma for clinical trial analytics and companion diagnostics — directly comparable to BostonGene's digital pathology and biopharma AI platform modules.
  • Owkin: Owkin operates an AI platform for patient stratification, biomarker discovery, and trial optimization serving biopharma — directly overlapping with BostonGene's biopharma target identification, biomarker discovery, and clinical trial support modules.
  • Paige AI: Paige builds AI-based digital pathology models including Paige Prostate (FDA-authorized) for cancer diagnosis and biopharma applications — directly comparable to BostonGene's AI-based digital pathology, IHC detection, and HER2 benchmarking work.

Broad incumbents

  • Guardant Health: Guardant Health is a liquid biopsy leader (Guardant360, Reveal) with a broader commercial footprint and FDA-approved diagnostics — overlapping with BostonGene's liquid biopsy (cfDNA/cfRNA) services but with established payer coverage and a public market scale BostonGene does not yet have.

Emerging players

  • Natera: Natera's Signatera MRD test and oncology offerings compete in molecular monitoring and treatment response — partial overlap with BostonGene's liquid biopsy and treatment-response monitoring services, primarily in the clinical rather than biopharma channel.
  • Recursion Pharmaceuticals: Recursion applies AI foundation models across multiomic and imaging data for drug discovery, with biopharma partnerships — adjacent to BostonGene's biopharma AI platform and foundation-model approach, though Recursion focuses more on therapeutic discovery rather than trial analytics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

BostonGene social profiles

Digital presence

BostonGene compliance and trust

Trust signal

Compliance4 records

BostonGene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BostonGene leadership team

Management profile

Number of profiles

Profiles5 records

BostonGene subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

BostonGene funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BostonGene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BostonGene

What does BostonGene do?

BostonGene provides a cloud-based AI-driven multimodal analytics platform that integrates whole exome sequencing, whole transcriptome sequencing, liquid biopsy, immune profiling, spatial proteomics, and digital pathology to analyze tumors, microenvironments, and host immunity. The company sells its BostonGene Tumor Portrait® test and related clinical assays to healthcare providers and oncologists, and offers AI-powered target identification, biomarker discovery, clinical trial support, and drug repurposing modules to biopharmaceutical partners via a subscription/enterprise model.

Is BostonGene a public or private company?

BostonGene is a private company. It is classified as venture growth investor backed and is currently operating.

When was BostonGene founded?

BostonGene was founded in 2015. It employs 251 to 500 people.

Where is BostonGene based?

BostonGene is headquartered in Waltham, United States, in the North America region.

How does BostonGene make money?

Two revenue lines are on record. Biopharma Partnerships and Platform Services are the primary driver. The others are clinical Laboratory Testing Services.

Who are BostonGene's main competitors?

Direct peers on record are Tempus AI, Foundation Medicine, Caris Life Sciences, Personalis, PathAI, Owkin and Paige AI. Guardant Health is listed as a broad incumbent. Emerging players are Natera and Recursion Pharmaceuticals.

Does BostonGene have an API?

No public API is recorded for BostonGene.

What industry is BostonGene in?

BostonGene's product category is Precision Oncology Analytics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogBostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026BostonGene will present two AI research abstracts at ESMO AI & Digital Oncology Congress 2026 in Berlin, November 16–18. The presentations cover a multimodal framework for tumor-of-origin classification from incomplete data and a pan-cancer deep learning approach for deconvolving bulk transcriptomes. The research was conducted in collaboration with Weill Cornell Medicine and Inova Schar Cancer Institute.FinancialContent Business PageBostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026BostonGene will present two AI research abstracts at ESMO AI & Digital Oncology Congress 2026 in Berlin, November 16–18. The presentations cover a multimodal framework for tumor-of-origin classification from incomplete data and a pan-cancer deep learning approach for deconvolving bulk transcriptomes. The company highlights its clinically validated AI platform for precision oncology.Business Wire BlogBostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease StratificationBostonGene will present new data on its biologically grounded AI at ACR Convergence 2026, held November 6–11 in Orlando. The company's pan-autoimmune transcriptomic atlas maps tissue architectures across immune-mediated inflammatory diseases, distinguishing shared immune features from tissue-specific drivers to enable patient stratification.FinancialContent Business PageBostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease StratificationBostonGene will present new data on its biologically grounded AI for non-oncology indications at ACR Convergence 2026 in Orlando. The company's pan-autoimmune transcriptomic atlas maps tissue architectures across immune-mediated inflammatory diseases, distinguishing shared immune features from tissue-specific drivers to enable patient stratification.Business Wire BlogBostonGene Wins Three Gold Stevie® AwardsBostonGene won three Gold Stevie Awards in 2026, including Company of the Year, New Product of the Year, and Technology Breakthrough of the Year. The awards recognize its AI platform that simulates tumor and immune responses to therapy before clinical testing. The company aims to reduce development risk and guide trial design.Business Wire BlogBostonGene CCO Dr. Ferran Prat to Moderate External Innovation Panel at Longwood Healthcare Leaders Boston CEO ConferenceBostonGene CCO Dr. Ferran Prat will moderate the "Ecosystem of External Innovation" panel at the Longwood Healthcare Leaders Boston CEO conference on November 2-3, 2026. The session will explore cross-industry partnerships, external science evaluation, and AI integration in drug development.FinancialContent Business PageBostonGene CCO Dr. Ferran Prat to Moderate External Innovation Panel at Longwood Healthcare Leaders Boston CEO ConferenceBostonGene's CCO Dr. Ferran Prat will moderate the "Ecosystem of External Innovation" panel at the Longwood Healthcare Leaders Boston CEO conference on November 2-3, 2026. The session will cover external scientific assets, cross-border data, regulatory dynamics, and AI integration, with panelists from Cullinan Therapeutics, UPMC Enterprises, and Prolium Bioscience.Business Wire BlogBostonGene and Medical University of South Carolina Announce Strategic Collaboration to Advance CAR-T Therapy Insights for Lymphoma and LeukemiaBostonGene and the Medical University of South Carolina announced a collaboration to use AI and multimodal immune profiling to identify biomarkers for CAR-T therapy response and toxicity. The phase Ib trial of a metabolically programmed CAR-T therapy for relapsed lymphoma showed a 67% complete remission rate with no grade 3+ CRS. The analyses aim to improve patient selection and predict adverse events.FinancialContent Business PageBostonGene and Medical University of South Carolina Announce Strategic Collaboration to Advance CAR-T Therapy Insights for Lymphoma and LeukemiaBostonGene and the Medical University of South Carolina announced a collaboration to use AI and multimodal immune profiling to study CAR-T therapy in lymphoma and leukemia. Preliminary data from a phase Ib trial showed a 67% complete remission rate with no grade 3+ cytokine release syndrome. The partnership aims to identify predictive biomarkers for response and toxicity.Business Wire BlogBostonGene Showcases Biologically Grounded AI at ESMO Congress 2026 to Advance Drug Development and Precision Clinical Decision-MakingBostonGene announced six accepted abstracts at ESMO Congress 2026, showcasing its AI platforms for tumor classification, resistance mechanisms, and personalized immunotherapy. The studies include RNA-seq phasing across 8,000 samples and a 50% response rate for a CCNG1-targeted CAR vector. The presentations aim to refine diagnostics and guide drug development.